Steven Grover on The Role of FXII in the Pathogenesis of VTE
Steven Grover, Staff Scientist II at Beth Israel Deaconess Medical Center, shared on LinkedIn:
”Evidence for a role of coagulation factor FXII in the pathogenesis of venous thromboembolism has proven elusive to date.
In work led by Amelia Haj from Tem Bendapudi’s group we show that germline heterozygous loss of function in FXII is associated with a significantly reduced risk of venous thromboembolism.
A 50% reduction in plasma FXII levels, although unremarkable in the classical activated partial thromboplastin time assay, is sufficient to significantly reduce plasma thrombin generation by calibrated automated thrombography and venous thrombosis in a preclinical model.
Delighted to have been involved in this important work alongside several researchers from the Blood Research Center at UNC, Beth Israel Deaconess Medical Center and Massachusetts General Hospital.
The paper is out now in Springer Nature journal Nature Communications, read it here”
Article: Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis
Authors: Amelia K. Haj, David S. Paul, Sean J. Jurgens, Harish Eswaran, Lu-Chen Weng, Justine Ryu, Alfonso Rodriguez Espada, Sharjeel Chaudhry, Louis M. Feingold, Kristen Burke, Satoshi Koyama, Xin Wang, Joyce Francis, Seung Hoan Choi, Nigel Mackman, Wolfgang Bergmeier, Alex Burgin, Joel T. Rämö, Patrick T. Ellinor, Steven Grover, Pavan K. Bendapudi
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025